EX-99.2 4 y96349exv99w2.txt SUPPLEMENTAL INFORMATION Exhibit 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES FIRST QUARTER 2004 NET PRODUCT SALES DETAIL (MILLIONS OF DOLLARS)
1Q '04 vs. 1Q '03 --------------------------------------------------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ MM % CHG $ MM % CHG $ MM ------- ------ ------ ------ ------ ------- ------- AGGRASTAT -2% $ 22 N/M -- 14% $ 22 ARCOXIA * 30 -- -- * 30 CANCIDAS 89% 88 84% 49 95% 39 COZAAR / HYZAAR -1% 629 -24% 216 19% 413 CRIXIVAN / STOCRIN -23% 64 -84% 6 30% 58 EMEND * 6 * 6 * 0 FOSAMAX -4% 759 -22% 442 39% 317 INVANZ * 12 77% 8 * 3 MAXALT -29% 56 -49% 30 31% 26 PRIMAXIN -8% 150 -53% 29 19% 121 PROPECIA -4% 63 -20% 29 15% 34 PROSCAR 34% 175 48% 84 23% 91 SINGULAIR 34% 623 28% 427 48% 196 TIMOPTIC / TIMOPTIC XE 6% 37 * 2 2% 35 TRUSOPT / COSOPT 25% 131 18% 52 30% 79 VASOTEC / VASERETIC 3% 173 N/M -- 0% 173 VIOXX 30% 661 28% 386 32% 275 ZOCOR 10% 1,296 41% 900 -26% 396 HEPATITIS VACCINES -8% 60 -5% 52 -25% 8 VIRAL VACCINES 0% 117 -3% 106 38% 11 OTHER VACCINES -12% 52 -15% 39 -1% 12
* > 100% N/M - Not Meaningful TOTAL SALES: VOLUME, PRICE, EXCHANGE
1Q '04 % CHG. VOL PX FX ------ ------ ------ ------ ------ TOTAL PHARMACEUTICAL SALES $5,631 1% -5 1 5 ------ ------ ------ ------ ------ U.S. ($ MM) 3,255 -5% -9 3 0 Foreign ($ MM) 2,376 12% 1 -2 13
Exhibit 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES FIRST QUARTER 2004 =============================================================================== OTHER (INCOME)/EXPENSE, NET FROM CONTINUING OPERATIONS (MILLIONS OF DOLLARS)
1Q '04 1Q '03 -------- -------- INTEREST INCOME $ (65.7) $ (87.4) INTEREST EXPENSE 72.8 95.2 EXCHANGE (GAINS)/LOSSES (7.8) (7.1) MINORITY INTERESTS 39.6 51.8 AMORTIZATION OF INTANGIBLES 37.3 31.3 Other, net (317.0) (36.0) -------- -------- TOTAL $ (240.9) $ 47.8
=============================================================================== JOINT VENTURE SALES DETAIL (MILLIONS OF DOLLARS) All sales reported here are end-market JV sales, presented on a "NET" basis.
MERIAL 1Q '04 1Q '03 ------ ------ IVOMEC, HEARTGARD, other avermectins $ 94 $ 97 FRONTLINE 161 132 Biologicals 113 103 Other Animal Health 51 47 Poultry Breeding 35 38 ------ ------ TOTAL MERIAL SALES $ 454 $ 417
AVENTIS PASTEUR-MSD 1Q '04 1Q '03 ------ ------ HEPATITIS VACCINES $ 20 $ 19 VIRAL VACCINES 13 11 Other Vaccines 120 90 ------ ------ TOTAL AP-MSD SALES $ 153 $ 120
MERCK / SCHERING-PLOUGH COLLABORATION 1Q '04 1Q '03 ------ ------ ZETIA (Worldwide) $ 190 $ 46 TOTAL $ 190 $ 46
===============================================================================